Modeling pancreatic cancer in mice for experimental therapeutics (original) (raw)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy that is characterized by early metastasis, low resectability, high recurrence, and therapy resistance. The experimental mouse models have played a central role in understanding the pathobiology of PDAC and in the preclinical evaluation of various therapeutic modalities. Different mouse models with targetable pathological hallmarks have been developed and employed to address the unique challenges associated with PDAC progression, metastasis, and stromal heterogeneity. Over the years, mouse models have evolved from simple cell line-based heterotopic and orthotopic xenografts in immunocompromised mice to more complex and realistic genetically engineered mouse models (GEMMs) involving multi-gene manipulations. The GEMMs, mostly driven by KRAS mutation(s), have been widely accepted for therapeutic optimization due to their high penetrance and ability to recapitulate the histological, molecular, and pathological hallmarks of human PDAC, including comparable precursor lesions, extensive metastasis, desmoplasia, perineural invasion, and immunosuppressive tumor microenvironment. Advanced GEMMs modified to express fluorescent proteins have allowed cell lineage tracing to provide novel insights and a new understanding about the origin and contribution of various cell types in PDAC pathobiology. The syngeneic mouse models, GEMMs, and target-specific transgenic mice have been extensively *

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (301)

Siegel RL, Miller KD, Jemal A, Cancer statistics, 2020, 70 (2020) 7-30.
Singhi AD, Koay EJ, Chari ST, Maitra A, Early Detection of Pancreatic Cancer: Opportunities and Challenges, Gastroenterology, 156 (2019) 2024-2040. [PubMed: 30721664]
Strobel O, Neoptolemos J, Jäger D, Büchler MW, Optimizing the outcomes of pancreatic cancer surgery, Nature Reviews Clinical Oncology, 16 (2019) 11-26.
Zhu H, Li T, Du Y, Li M, Pancreatic cancer: challenges and opportunities, BMC Med, 16 (2018) 214-214. [PubMed: 30463539]
Karamitopoulou E, Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features, British Journal of Cancer, 121 (2019) 5-14. [PubMed: 31110329]
Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS, Liu A, Vincent Jordan N, Franses JW, Philipp J, Kreuzer J, Desai N, Arora KS, Rajurkar M, Horwitz E, Neyaz A, Tai E, Magnus NKC, Vo KD, Yashaswini CN, Marangoni F, Boukhali M, Fatherree JP, Damon LJ, Xega K, Desai R, Choz M, Bersani F, Langenbucher A, Thapar V, Morris R, Wellner UF, Schilling O, Lawrence MS, Liss AS, Rivera MN, Deshpande V, Benes CH, Maheswaran S, Haber DA, Fernandez-Del-Castillo C, Ferrone CR, Haas W, Aryee MJ, Ting DT, Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer, Cell, 178 (2019) 160-175.e127. [PubMed: 31155233]
Nia HT, Munn LL, Jain RK, Mapping Physical Tumor Microenvironment and Drug Delivery, Clinical Cancer Research, (2019).
Wei L, Ye H, Li G, Lu Y, Zhou Q, Zheng S, Lin Q, Liu Y, Li Z, Chen R, Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer, Cell Death & Disease, 9 (2018) 1065. [PubMed: 30337520]
Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I, Role of the tumor microenvironment in pancreatic cancer, Ann Gastroenterol Surg, 3 (2019) 130-137. [PubMed: 30923782]
Davies G, Duke D, Grant AG, Kelly SA, Hermon-Taylor J, Growth of human digestive-tumour xenografts in athymic nude rats, Br J Cancer, 43 (1981) 53-58. [PubMed: 7459238]
Satake K, Mukai R, Kato Y, Shim K, Umeyama K, Experimental pancreatic carcinoma as a model of human pancreatic carcinoma, Clinical oncology, 10 (1984) 27-34. [PubMed: 6423332]
Marincola FM, Drucker BJ, Siao DY, Hough KL, Holder WD Jr., The nude mouse as a model for the study of human pancreatic cancer, The Journal of surgical research, 47 (1989) 520-529. [PubMed: 2586101]
Vezeridis MP, Doremus CM, Tibbetts LM, Tzanakakis G, Jackson BT, Invasion and metastasis following orthotopic transplantation of human pancreatic cancer in the nude mouse, Journal of surgical oncology, 40 (1989) 261-265. [PubMed: 2927139]
Rivera JA, Graeme-Cook F, Werner J, Z'Graggen K, Rustgi AK, Rattner DW, Warshaw AL, Fernández-del Castillo C, A rat model of pancreatic ductal adenocarcinoma: targeting chemical carcinogens, Surgery, 122 (1997) 82-90. [PubMed: 9225919]
Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, Ellenhorn JD, An orthotopic in vivo model of human pancreatic cancer, Surgery, 126 (1999) 562-567. [PubMed: 10486610]
Yamamura S, Onda M, Uchida E, Two types of peritoneal dissemination of pancreatic cancer cells in a hamster model, Nihon Ika Daigaku zasshi, 66 (1999) 253-261. [PubMed: 10466341]
Mohammad RM, Al-Katib A, Pettit GR, Vaitkevicius VK, Joshi U, Adsay V, Majumdar AP, Sarkar FH, An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies, Clinical cancer research : an official journal of the American Association for Cancer Research, 4 (1998) 887-894. [PubMed: 9563882]
Cardillo TM, Ying Z, Gold DV, Therapeutic advantage of (90)yttrium-versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, 7 (2001) 3186-3192. [PubMed: 11595713]
Kong K, Guo M, Liu Y, Zheng J, Progress in Animal Models of Pancreatic Ductal Adenocarcinoma, J Cancer, 11 (2020) 1555-1567. [PubMed: 32047562]
Fu X, Guadagni F, Hoffman RM, A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens, Proceedings of the National Academy of Sciences of the United States of America, 89 (1992) 5645-5649. [PubMed: 1608975]
Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman RM, A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice, Cancer research, 53 (1993) 3070-3072. [PubMed: 8319214]
Garcia PL, Miller AL, Yoon KJ, Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models, Cancers, 12 (2020) 1327.
Rajeshkumar NV, Yabuuchi S, Pai SG, De Oliveira E, Kamphorst JJ, Rabinowitz JD, Tejero H, Al-Shahrour F, Hidalgo M, Maitra A, Dang CV, Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin, Clinical Cancer Research, 23 (2017) 5639. [PubMed: 28611197]
Witkiewicz Agnieszka K., Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills Gordon B., O'Reilly Eileen M., Knudsen Erik S., Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer, Cell Reports, 16 (2016) 2017- 2031. [PubMed: 27498862]
An Z, Wang X, Kubota T, Moossa AR, Hoffman RM, A clinical nude mouse metastatic model for highly malignant human pancreatic cancer, Anticancer research, 16 (1996) 627-631. [PubMed: 8687107]
Kimura Y, Kobari M, Yusa T, Sunamura M, Kimura M, Shimamura H, Matsuno S, Establishment of an experimental liver metastasis model by intraportal injection of a newly derived human pancreatic cancer cell line (KLM-1), International journal of pancreatology : official journal of the International Association of Pancreatology, 20 (1996) 43-50. [PubMed: 8872523]
Hwang RF, Gordon EM, Anderson WF, Parekh D, Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene, Surgery, 124 (1998) 143-150; discussion 150-141. [PubMed: 9706132]
Uprety D, Adjei AA, KRAS: From undruggable to a druggable Cancer Target, Cancer treatment reviews, 89 (2020) 102070. [PubMed: 32711246]
Buscail L, Bournet B, Cordelier P, Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer, Nat Rev Gastroenterol Hepatol, 17 (2020) 153-168. [PubMed: 32005945]
Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T, Somatic activation of the K-ras oncogene causes early onset lung cancer in mice, Nature, 410 (2001) 1111-1116. [PubMed: 11323676]
Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA, Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse, Cancer cell, 4 (2003) 437-450. [PubMed: 14706336]
Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer cell, 7 (2005) 469-483. [PubMed: 15894267]
Ray P, Rialon-Guevara KL, Veras E, Sullenger BA, White RR, Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker, The Journal of Clinical Investigation, 122 (2012) 1734-1741. [PubMed: 22484812]
Mirus JE, Zhang Y, Li C.l., Lokshin AE, Prentice RL, Hingorani SR, Lampe PD, Cross-Species Antibody Microarray Interrogation Identifies a 3-Protein Panel of Plasma Biomarkers for Early Diagnosis of Pancreas Cancer, Clinical Cancer Research, 21 (2015) 1764. [PubMed: 25589628]
Ligat L, Saint-Laurent N, El-Mrani A, Gigoux V, Al Saati T, Tomasini R, Nigri J, Dejean S, Pont F, Baer R, Guillermet-Guibert J, Cordelier P, Lopez F, Dufresne M, Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models, British Journal of Cancer, 113 (2015) 1590-1598. [PubMed: 26512875]
Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R, Soluble stroma related biomarkers of pancreatic cancer, EMBO Molecular Medicine, 10 (2018) e8741. [PubMed: 29941541]
Song X, Zhu S, Xie Y, Liu J, Sun L, Zeng D, Wang P, Ma X, Kroemer G, Bartlett DL, Billiar TR, Lotze MT, Zeh HJ, Kang R, Tang D, JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice, Gastroenterology, 154 (2018) 1480-1493. [PubMed: 29248440]
Jiang H, Liu X, Knolhoff BL, Hegde S, Lee KB, Jiang H, Fields RC, Pachter JA, Lim KH, DeNardo DG, Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion, Gut, 69 (2020) 122-132. [PubMed: 31076405]
Nagathihalli NS, Castellanos JA, Lamichhane P, Messaggio F, Shi C, Dai X, Rai P, Chen X, VanSaun MN, Merchant NB, Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer, Cancer research, 78 (2018) 6235- 6246. [PubMed: 30154150]
Olive KP, Tuveson DA, The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics, Clinical Cancer Research, 12 (2006) 5277. [PubMed: 17000660]
Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT, Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti- PD-L1 immunotherapy in pancreatic cancer, Proceedings of the National Academy of Sciences, 110 (2013) 20212.
Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz Monserrate Z, Yu L, Young G, Zhong X, Zimmers TA, Ostrowski MC, Ludwig T, Bloomston M, Bekaii-Saab T, Lesinski GB, IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer, Gut, 67 (2018) 320-332. [PubMed: 27797936]
Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, Perconti G, Feo S, Giovarelli M, Novelli F, Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer, Gastroenterology, 144 (2013) 1098-1106. [PubMed: 23333712]
Soares KC, Rucki AA, Kim V, Foley K, Solt S, Wolfgang CL, Jaffee EM, Zheng L, TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner, Oncotarget, 6 (2015) 43005-43015. [PubMed: 26515728]
Keenan BP, Saenger Y, Kafrouni M.l., Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW, Hassan R, Armstrong TD, Jaffee EM, A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice, Gastroenterology, 146 (2014) 1784-1794.e1786. [PubMed: 24607504]
Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH, CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans, Science, 331 (2011) 1612. [PubMed: 21436454]
Dauer P, Zhao X, Gupta VK, Sharma N, Kesh K, Gnamlin P, Dudeja V, Vickers SM, Banerjee S, Saluja A, Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression, Cancer research, 78 (2018) 1321-1333. [PubMed: 29259015]
Torres MP, Rachagani S, Souchek JJ, Mallya K, Johansson SL, Batra SK, Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy, PLoS One, 8 (2013) e80580. [PubMed: 24278292]
Tiriac H, Plenker D, Baker LA, Tuveson DA, Organoid models for translational pancreatic cancer research, Current opinion in genetics & development, 54 (2019) 7-11. [PubMed: 30844513]
Tiriac H, Belleau P, Engle DD, Plenker D, Deschenes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA, Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer, Cancer discovery, 8 (2018) 1112-1129. [PubMed: 29853643]
Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA, Organoid models of human and mouse ductal pancreatic cancer, Cell, 160 (2015) 324-338. [PubMed: 25557080]
Li J, Qian W, Qin T, Xiao Y, Cheng L, Cao J, Chen X, Ma Q, Wu Z, Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo, Computational and structural biotechnology journal, 17 (2019) 498-506. [PubMed: 31011408]
Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quiros Fernandez S, Lau A, Richards FM, Jodrell DI, The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression, Molecular cancer therapeutics, 17 (2018) 1670-1682. [PubMed: 29891488]
Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, Alagesan B, Lee EJ, Yao MA, Lucito MS, Spielman B, Da Silva B, Schoepfer C, Wright K, Creighton B, Afinowicz L, Yu KH, Grützmann R, Aust D, Gimotty PA, Pollard KS, Hruban RH, Goggins MG, Pilarsky C, Park Y, Pappin DJ, Hollingsworth MA, Tuveson DA, The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice, Science, 364 (2019) 1156-1162. [PubMed: 31221853]
Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG, Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy, Nature medicine, 22 (2016) 851-860.
Kim VM, Blair AB, Lauer P, Foley K, Che X, Soares K, Xia T, Muth ST, Kleponis J, Armstrong TD, Wolfgang CL, Jaffee EM, Brockstedt D, Zheng L, Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies, Journal for ImmunoTherapy of Cancer, 7 (2019) 132. [PubMed: 31113479]
Yasmin-Karim S, Bruck PT, Moreau M, Kunjachan S, Chen GZ, Kumar R, Grabow S, Dougan SK, Ngwa W, Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer, Front. Immunol, 9 (2018).
Yang J, Hu S, Shangguan J, Eresen A, Li Y, Pan L, Ma Q, Velichko Y, Wang J, Hu C, Yaghmai V, Zhang Z, Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma, Am J Cancer Res, 9 (2019) 2456-2468. [PubMed: 31815046]
Ma Y, Li J, Wang H, Chiu Y, Kingsley CV, Fry D, Delaney SN, Wei SC, Zhang J, Maitra A, Yee C, Combination of PD1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer, Gastroenterology, (2020).
Azad A, Yin Lim S, D'Costa Z, Jones K, Diana A, Sansom OJ, Kruger P, Liu S, McKenna WG, Dushek O, Muschel RJ, Fokas E, PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy, EMBO molecular medicine, 9 (2017) 167-180. [PubMed: 27932443]
Sivaram N, McLaughlin PA, Han HV, Petrenko O, Jiang YP, Ballou LM, Pham K, Liu C, van der Velden AW, Lin RZ, Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer, J Clin Invest, 129 (2019) 3264-3276. [PubMed: 31112530]
Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tahtinen S, Hemminki A, June CH, Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses, JCI Insight, 3 (2018) e99573.
Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, Porterfield Kren N, Michaud D, Ahn S, Vincent B, Savoldo B, Pylayeva-Gupta Y, Zhang S, Dotti G, Xu Y, Interleukin-23 engineering improves CAR T cell function in solid tumors, Nature Biotechnology, 38 (2020) 448-459.
Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MCJ, Robertson AJ, Fadlullah MZH, Bruxner TJC, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, lacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempera MA, Biankin AV, Johns AL, Mawson A, Chang DK, Scarlett CJ, Brancato M-AL, Rowe SJ, Simpson SH, Martyn-Smith M, Thomas MT, Chantrill LA, Chin VT, Chou A, Cowley MJ, Humphris JL, Jones MD, Scott Mead R, Nagrial AM, Pajic M, Pettit J, Pinese M, Rooman I, Wu J, Tao J, DiPietro R, Watson C, Steinmann A, Ching Lee H, Wong R, Pinho AV, Giry-Laterriere M, Daly RJ, Musgrove EA, Sutherland RL, Grimmond SM, Waddell N, Kassahn KS, Miller DK, Wilson PJ, Patch A-M, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu C, Nones K, Lynn Fink J, Christ A, Bruxner T, Cloonan N, Newell F, Pearson JV, Bailey P, Quinn M, Nagaraj S, Kazakoff S, Waddell N, Krisnan K, Quek K, Wood D, Fadlullah MZH, Samra JS, Gill AJ, Pavlakis N, Guminski A, Toon C, Asghari R, Merrett ND, Pavey D, Das A, Cosman PH, Ismail K, O'Connnor C, Lam Duncan McLeod VW, Pleass HC, Richardson A, James V, Kench JG, Cooper CL, Joseph D, Sandroussi C, Crawford M, Gallagher J, Texler M, Forest C, Laycock A, Epari KP, Ballal M, Fletcher DR, Mukhedkar S, Spry NA, DeBoer B, Chai M, Zeps N, Beilin M, Feeney K, Nguyen NQ, Ruszkiewicz AR, Worthley C, Tan CP, Debrencini T, Chen J, Brooke-Smith ME, Papangelis V, Tang H, Barbour AP, Clouston AD, Martin P, O'Rourke TJ, Chiang A, Fawcett JW, Slater K, Yeung S, Hatzifotis M, Hodgkinson P, Christophi C, Nikfarjam M, Mountain A, Eshleman JR, Hruban RH, Maitra A, lacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Hodgin M, Scarpa A, Lawlor RT, Beghelli S, Corbo V, Scardoni M, Bassi C, Tempera MA, Biankin AV, Grimmond SM, Chang DK, Musgrove EA, Jones MD, Nourse C, Jamieson NB, Graham JS, Biankin AV, Chang DK, Jamieson NB, Graham JS, Oien K, Hair J, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM, I. Australian Pancreatic Cancer Genome, R. Garvan Institute of Medical, B. Queensland Centre for Medical Genomics / Institute for Molecular, H. Royal North Shore, H. Bankstown, H. Liverpool, H. Westmead, H. Royal Prince Alfred, Fremantle H, H. Sir Charles Gairdner, H. St John of God, H. Royal Adelaide, C. Flinders Medical, H. Greenslopes Private, P. Envoi, H. Princess Alexandria, H. Austin, B. Victorian Cancer, I. Johns Hopkins Medical, A.R.-N.C.f.A.R.o. Cancer, S.F. University of California, G. University of, G. Greater, S. Clyde National Health, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518 (2015) 495-501. [PubMed: 25719666]
Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O'Kane GM, Connor AA, Denroche RE, Grant RC, McLeod J, Wilson JM, Jang GH, Zhang A, Dodd A, Liang S-B, Borgida A, Chadwick D, Kalimuthu S, Lungu I, Bartlett JMS, Krzyzanowski PM, Sandhu V, Tiriac H, Froeling FEM, Karasinska JM, Topham JT, Renouf DJ, Schaeffer DF, Jones SJM, Marra MA, Laskin J, Chetty R, Stein LD, Zogopoulos G, Haibe-Kains B, Campbell PJ, Tuveson DA, Knox JJ, Fischer SE, Gallinger S, Notta F, Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution, Nature Genetics, 52 (2020) 231-240. [PubMed: 31932696]
Chen K, Qian W, Jiang Z, Cheng L, Li J, Sun L, Zhou C, Gao L, Lei M, Yan B, Cao J, Duan W, Ma Q, Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer, Mol Cancer, 16 (2017) 131-131. [PubMed: 28738823]
Brereton MF, Rohm M, Shimomura K, Holland C, Tornovsky-Babeay S, Dadon D, Iberl M, Chibalina MV, Lee S, Glaser B, Dor Y, Rorsman P, Clark A, Ashcroft FM, Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic β-cells, NatCommun, 7 (2016) 13496.
Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Poliak MN, Hursting SD, Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms, Diabetes, 64 (2015) 1632-1642. [PubMed: 25576058]
Wang L, Bai YY, Yang Y, Hu F, Wang Y, Yu Z, Cheng Z, Zhou J, Diabetes mellitus stimulates pancreatic cancer growth and epithelial-mesenchymal transition-mediated metastasis via a p38 MAPK pathway, Oncotarget, 7 (2016) 38539-38550. [PubMed: 27413117]
Edderkaoui M, Xu S, Chheda C, Morvaridi S, Hu RW, Grippo PJ, Mascariñas E, Principe DR, Knudsen B, Xue J, Habtezion A, Uyeminami D, Pinkerton KE, Pandol SJ, HDAC3 mediates smoking-induced pancreatic cancer, Oncotarget, 7 (2016) 7747-7760. [PubMed: 26745602]
Kumar S, Torres MP, Kaur S, Rachagani S, Joshi S, Johansson SL, Momi N, Baine MJ, Gilling CE, Smith LM, Wyatt TA, Jain M, Joshi SS, Batra SK, Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages, Oncogene, 34 (2015) 2052-2060. [PubMed: 24909166]
Xu S, Chheda C, Ouhaddi Y, Benhaddou H, Bourhim M, Grippo PJ, Principe DR, Mascarinas E, DeCant B, Tsukamoto H, Pandol SJ, Edderkaoui M, Characterization of Mouse Models of Early Pancreatic Lesions Induced by Alcohol and Chronic Pancreatitis, Pancreas, 44 (2015) 882-887. [PubMed: 26166469]
Ho WJ, Jaffee EM, Zheng L, The tumour microenvironment in pancreatic cancer -clinical challenges and opportunities, Nature Reviews Clinical Oncology, (2020).
Bisht S, Feldmann G, Animal models for modeling pancreatic cancer and novel drug discovery, Expert Opinion on Drug Discovery, 14 (2019) 127-142. [PubMed: 30657339]
Saluja AK, Dudeja V, Relevance of animal models of pancreatic cancer and pancreatitis to human disease, Gastroenterology, 144 (2013) 1194-1198. [PubMed: 23622128]
Kalapothaki V, Tzonou A, Hsieh C.-c., Toupadaki N, Karakatsani A, Trichopoulos D, Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma, Cancer Causes & Control, 4 (1993) 375-382. [PubMed: 8347787]
Maisonneuve P, Lowenfels AB, Risk factors for pancreatic cancer: a summary review of meta-analytical studies, International Journal of Epidemiology, 44 (2014) 186-198. [PubMed: 25502106]
Momi N, Kaur S, Krishn SR, Batra SK, Discovering the route from inflammation to pancreatic cancer, Minerva Gastroenterol Dietol, 58 (2012) 283-297. [PubMed: 23207606]
Li J.-s., Liu F, The Relationship of Acute Pancreatitis and Pancreatic Cancer, Pancreas, 48 (2019).
Aigul H, Treiber M, Lesina M, Schmid RM, Mechanisms of Disease: chronic inflammation and cancer in the pancreas-a potential role for pancreatic stellate cells?, Nature Clinical Practice Gastroenterology & Hepatology, 4 (2007) 454-462.
Klauss S, Schorn S, Teller S, Steenfadt H, Friess H, Ceyhan GO, Demir IE, Genetically induced vs. classical animal models of chronic pancreatitis: a critical comparison, The FASEB Journal, 32 (2018) 5778-5792.
Leal AS, Liby KT, Murine Models of Pancreatitis Leading to the Development of Pancreatic Cancer, Curr Protoc Pharmacol, 83 (2018) e48. [PubMed: 30325112]
Lerch MM, Gorelick FS, Models of Acute and Chronic Pancreatitis, Gastroenterology, 144 (2013) 1180-1193. [PubMed: 23622127]
Lampel M, Kern HF, Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue, Virchows Archiv. A, Pathological anatomy and histology, 373 (1977) 97-117. [PubMed: 139754]
Swidnicka-Siergiejko AK, Gomez-Chou SB, Cruz-Monserrate Z, Deng D, Liu Y, Huang H, Ji B, Azizian N, Daniluk J, Lu W, Wang H, Maitra A, Logsdon CD, Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53, Oncogene, 36 (2017) 3149-3158. [PubMed: 27991926]
Ahmadi A, Nikkhoo B, Mokarizadeh A, Rahmani M-R, Fakhari S, Mohammadi M, Jalili A, An optimised mouse model of chronic pancreatitis with a combination of ethanol and cerulein, Cent Eur J Immunol, 41 (2016) 54-63. [PubMed: 27095923]
Steele CW, Karim SA, Foth M, Rishi L, Leach JD, Porter RJ, Nixon C, Jeffry Evans T, Carter CR, Nibbs RJ, Sansom OJ, Morton JP, CXCR2 inhibition suppresses acute and chronic pancreatic inflammation, 237 (2015) 85-97.
Komar HM, Serpa G, Kerscher C, Schwoegl E, Mace TA, Jin M, Yang M-C, Chen C-S, Bloomston M, Ostrowski MC, Hart PA, Conwell DL, Lesinski GB, Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo, Scientific Reports, 7 (2017) 1787. [PubMed: 28496202]
Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ, Phenotype and genotype of pancreatic cancer cell lines, Pancreas, 39 (2010) 425-435. [PubMed: 20418756]
Kim S-C, Shin Y-K, Kim S-W, Seo H-Y, Kwon W, Kim H, Han Y, Lee J-O, Jang J-Y, Ku J-L, Establishment and Characterization of 10 Human Pancreatic Cancer Cell Lines Including a HER2 Overexpressed Cell Line, Pancreas, 48 (2019).
Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, Mansour J, Witkiewicz AK, Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility, Gut, 67 (2018) 508. [PubMed: 28073890]
Swayden M, Soubeyran P, lovanna J, Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma, Frontiers in oncology, 9 (2020).
Moriya C, Taniguchi H, Miyata K, Nishiyama N, Kataoka K, Imai K, Inhibition of PRDM14 expression in pancreatic cancer suppresses cancer stem-like properties and liver metastasis in mice, Carcinogenesis, 38 (2017) 638-648. [PubMed: 28498896]
Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW, Whang EE, Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer, Ann Surg, 240 (2004) 667-676. [PubMed: 15383794]
Morimoto M, Horikoshi Y, Nakaso K, Kurashiki T, Kitagawa Y, Hanaki T, Sakamoto T, Honjo S, Umekita Y, Fujiwara Y, Matsura T, Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer, Cancer Letters, 470 (2020) 149-160. [PubMed: 31765735]
Santoro R, Zanotto M, Simionato F, Zecchetto C, Merz V, Cavallini C, Piro G, Sabbadini F, Boschi F, Scarpa A, Melisi D, Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer, Molecular cancer therapeutics, 19 (2020) 247. [PubMed: 31562256]
Lee D-E, Yoo JE, Kim J, Kim S, Kim S, Lee H, Cheong H, NEDD4L downregulates autophagy and cell growth by modulating ULK1 and a glutamine transporter, Cell Death & Disease, 11 (2020) 38. [PubMed: 31959741]
Dosch AR, Dai X, Reyzer ML, Mehra S, Srinivasan S, Willobee BA, Kwon D, Kashikar N, Caprioli R, Merchant NB, Nagathihalli NS, Combined Src/EGFR inhibition targets STAT3 signaling and induces stromal remodeling to improve survival in pancreatic cancer, Molecular Cancer Research, (2020) molcanres.0741.2019.
Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E, Mutant KRAS is a druggable target for pancreatic cancer, Proceedings of the National Academy of Sciences, 110 (2013) 20723.
Kumarasamy V, Ruiz A, Nambiar R, Witkiewicz AK, Knudsen ES, Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer, Oncogene, 39 (2020) 1831-1845. [PubMed: 31745297]
Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Muller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U, SUMO pathway inhibition targets an aggressive pancreatic cancer subtype, Gut, (2020) gutjnl-2018-317856.
Gibson AR, Leary BR, Du J, Sarsour EH, Kalen AL, Wagner BA, Stolwijk JM, Falls-Hubert KC, Alexander MS, Carroll RS, Spitz DR, Buettner GR, Goswami PC, Cullen JJ, Dual Oxidase Induced Sustained Generation of Hydrogen Peroxide Contributes to Pharmacologic Ascorbate Induced Cytotoxicity, Cancer research, 80 (2020) 1401. [PubMed: 32041838]
Lipner MB, Peng XL, Jin C, Xu Y, Gao Y, East MP, Rashid NU, Moffitt RA, Herrera Loeza SG, Morrison AB, Golitz BT, Vaziri C, Graves LM, Johnson GL, Yeh JJ, Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy, JCI Insight, 5 (2020).
Ricciardiello F, Gang Y, Palorini R, Li Q, Giampá M, Zhao F, You L, La Ferla B, De Vitto H, Guan W, Gu J, Zhang T, Zhao Y, Chiaradonna F, Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation, Oncogene, (2020).
Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R, Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer, Nature, 546 (2017) 498-503. [PubMed: 28607485]
Wang FT, Sun W, Zhang JT, Fan YZ, Cancer-associated fibroblast regulation of tumor neo angiogenesis as a therapeutic target in cancer, Oncology letters, 17 (2019) 3055-3065. [PubMed: 30867734]
Whittle MC, Hingorani SR, Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets, Gastroenterology, 156 (2019) 2085-2096. [PubMed: 30721663]
Pausch TM, Aue E, Wirsik NM, Freire Valls A, Shen Y, Radhakrishnan P, Hackert T, Schneider M, Schmidt T, Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes, Scientific Reports, 10 (2020) 5420. [PubMed: 32214219]
Raimondi G, Mato-Berciano A, Pascual-Sabater S, Rovira-Rigau M, Cuatrecasas M, Fondevila C, Sánchez-Cabús S, Begthel H, Boj SF, Clevers H, Fillat C, Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses, EBioMedicine, 56 (2020).
Driehuis E, van Hoeck A, Moore K, Kolders S, Francies HE, Gulersonmez MC, Stigter ECA, Burgering B, Geurts V, Gracanin A, Bounova G, Morsink FH, Vries R, Boj S, van Es J, Offerhaus GJA, Kranenburg O, Garnett MJ, Wessels L, Cuppen E, Brosens LAA, Clevers H, Pancreatic cancer organoids recapitulate disease and allow personalized drug screening, Proceedings of the National Academy of Sciences, 116 (2019) 26580.
Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, French R, Lowy AM, Engleman EG, Development of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host, Clinical Cancer Research, 16 (2010) 3684. [PubMed: 20534740]
Miyabayashi K, Baker LA, Deschênes A, Traub B, Caligiuri G, Plenker D, Alagesan B, Belleau P, Li S, Kendall J, Jang GH, Kawaguchi RK, Somerville TDD, Tiriac H, Hwang C-I, Burkhart RA, Roberts NJ, Wood LD, Hruban RH, Gillis J, Krasnitz A, Vakoc CR, Wigler M, Notta F, Gallinger S, Park Y, Tuveson DA, Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes, Cancer discovery, 10 (2020) 1566. [PubMed: 32703770]
Guerin MV, Finisguerra V, Van den Eynde BJ, Bercovici N, Trautmann A, Preclinical murine tumor models: A structural and functional perspective, eLife, 9 (2020) e50740. [PubMed: 31990272]
Erstad DJ, Sojoodi M, Taylor MS, Ghoshal S, Razavi AA, Graham-O'Regan KA, Bardeesy N, Ferrone CR, Lanuti M, Caravan P, Tanabe KK, Fuchs BC, Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy, Disease models & mechanisms, 11 (2018).
Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L, Mouse models of pancreatic cancer, World J Gastroenterol, 18 (2012) 1286-1294. [PubMed: 22493542]
Zhang W, Fan W, Rachagani S, Zhou Z, Lele SM, Batra SK, Garrison JC, Comparative Study of Subcutaneous and Orthotopic Mouse Models of Prostate Cancer: Vascular Perfusion, Vasculature Density, Hypoxic Burden and BB2r-Targeting Efficacy, Scientific Reports, 9 (2019) 11117. [PubMed: 31366895]
Grbovic-Huezo O, Pitter KL, Lecomte N, Saglimbeni J, Askan G, Holm M, Melchor JP, Chandwani R, Joshi S, Haglund C, lacobuzio-Donahue CA, Chiosis G, Tammela T, Leach SD, Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma, Proceedings of the National Academy of Sciences, 117 (2020) 30670.
Maeda A, Chen Y, Bu J, Mujcic H, Wouters BG, DaCosta RS, In Vivo Imaging Reveals Significant Tumor Vascular Dysfunction and Increased Tumor Hypoxia-Inducible Factor-1α Expression Induced by High Single-Dose Irradiation in a Pancreatic Tumor Model, International Journal of Radiation Oncology*Biology*Physics, 97 (2017) 184-194.
Fridman R, Benton G, Aranoutova I, Kleinman HK, Bonfil RD, Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection, Nat Protoc, 7 (2012) 1138-1144. [PubMed: 22596226]
Benton G, Kleinman HK, George J, Arnaoutova I, Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells, International Journal of Cancer, 128 (2011) 1751-1757. [PubMed: 21344372]
Burrack AL, Spartz EJ, Raynor JF, Wang I, Olson M, Stromnes IM, Combination PD-1 and PD L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma, Cell Rep, 28 (2019) 2140-2155.e2146. [PubMed: 31433988]
Hay CA, Sor R, Flowers AJ, Clendenin C, Byrne KT, Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma, JoVE, (2019) e60497.
McVeigh LE, Wijetunga I, Ingram N, Marston G, Prasad R, Markham AF, Coletta PL, Development of orthotopic tumour models using ultrasound-guided intrahepatic injection,
Tuveson David A., Neoptolemos John P., Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches, Cell, 148 (2012) 21-23. [PubMed: 22265397]
Yachida S, lacobuzio-Donahue CA, The Pathology and Genetics of Metastatic Pancreatic Cancer, 133 (2009) 413-422.
Büchler P, Reber HA, Lavey RS, Tomlinson J, Buchler MW, Friess H, Hines OJ, Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model, The Journal of surgical research, 120 (2004) 295-303. [PubMed: 15234226]
Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M, An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer, Clinical & experimental metastasis, 21 (2004) 7-12. [PubMed: 15065597]
Higuchi T, Yokobori T, Naito T, Kakinuma C, Hagiwara S, Nishiyama M, Asao T, Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT-2 pancreatic cancer mouse model, Oncology letters, 15 (2018) 3091- 3099. [PubMed: 29435042]
Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, Jaffee E, Schulick RD, Yoshimura K, Edil B, Zheng L, A preclinical murine model of hepatic metastases, J Vis Exp, (2014) 51677- 51677. [PubMed: 25285458]
Enomoto T, Oda T, Aoyagi Y, Sugiura S, Nakajima M, Satake M, Noguchi M, Ohkohchi N, Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells, Cancer research, 66 (2006) 11131-11139. [PubMed: 17145856]
Mierke F, Hempel S, Distler M, Aust DE, Saeger HD, Weitz J, Welsch T, Impact of Portal Vein Involvement from Pancreatic Cancer on Metastatic Pattern After Surgical Resection, Annals of surgical oncology, 23 (2016) 730-736. [PubMed: 27554501]
Goddard ET, Fischer J, Schedin P, A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer, J Vis Exp, (2016) 54903.
Enomoto T, Oda T, Aoyagi Y, Sugiura S, Nakajima M, Satake M, Noguchi M, Ohkohchi N, Consistent Liver Metastases in a Rat Model by Portal Injection of Microencapsulated Cancer Cells, Cancer research, 66 (2006) 11131. [PubMed: 17145856]
Limani P, Borgeaud N, Linecker M, Tschuor C, Kachaylo E, Schlegel A, Jang J-H, Ungethum U, Montani M, Graf R, Humar B, Clavien P-A, Selective portal vein injection for the design of syngeneic models of liver malignancy, American Journal of Physiology-Gastrointestinal and Liver Physiology, 310 (2016) G682-G688. [PubMed: 26893160]
Sugase T, Lam BQ, Danielson M, Terai M, Aplin AE, Gutkind JS, Sato T, Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma, Journal of Translational Medicine, 18 (2020) 208. [PubMed: 32434572]
Hegde S, Krisnawan VE, Herzog BH, Zuo C, Breden MA, Knolhoff BL, Hogg GD, Tang JP, Baer JM, Mpoy C, Lee KB, Alexander KA, Rogers BE, Murphy KM, Hawkins WG, Fields RC, DeSelm CJ, Schwarz JK, DeNardo DG, Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer, Cancer cell, 37 (2020) 289-307.e289. [PubMed: 32183949]
Chen SH, Zhang BY, Zhou B, Zhu CZ, Sun LQ, Feng YJ, Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche, American journal of cancer research, 9 (2019) 1-21. [PubMed: 30755808]
Tan X, Sivakumar S, Bednarsch J, Wiltberger G, Kather JN, Niehues J, de Vos-Geelen J, Valkenburg-van Iersel L, Kintsler S, Roeth A, Hao G, Lang S, Coolsen ME, den Dulk M, Aberle MR, Koolen J, Gaisa NT, Olde Damink SWM, Neumann UP, Heij LR, Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma, Oncogene, 40 (2021) 899-908. [PubMed: 33288884]
Bapat AA, Hostetter G, Von Hoff DD, Han H, Perineural invasion and associated pain in pancreatic cancer, Nature Reviews Cancer, 11 (2011) 695-707. [PubMed: 21941281]
Matsuda M, Nimura Y, Perineural invasion of pancreas head carcinoma, Nihon Geka Gakkai Zasshi, 84 (1983) 719-728. [PubMed: 6676638]
Pour PM, Egami H, Takiyama Y, Patterns of growth and metastases of induced pancreatic cancer in relation to the prognosis and its clinical implications, Gastroenterology, 100 (1991) 529-536. [PubMed: 1985049]
Okada Y, Eibl G, Guha S, Duffy JP, Reber HA, Hines OJ, Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells, Clinical & experimental metastasis, 21 (2004) 285-292. [PubMed: 15554384]
Swanson BJ, McDermott KM, Singh PK, Eggers JP, Crocker PR, Hollingsworth MA, MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion, Cancer research, 67 (2007) 10222-10229. [PubMed: 17974963]
Li J, Ma Q, Hyperglycemia promotes the perineural invasion in pancreatic cancer, Med Hypotheses, 71 (2008) 386-389. [PubMed: 18571873]
Abiatari I, Gillen S, DeOliveira T, Klose T, Bo K, Giese NA, Friess H, Kleeff J, The microtubule-associated protein MAPRE2 is involved in perineural invasion of pancreatic cancer cells, International journal of oncology, 35 (2009) 1111-1116. [PubMed: 19787265]
Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, Yuan YZ, Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma, Annals of surgical oncology, 17 (2010) 2213-2221. [PubMed: 20162456]
Li X, Ma G, Ma Q, Li W, Liu J, Han L, Duan W, Xu Q, Liu H, Wang Z, Sun Q, Wang F, Wu E, Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells, Mol Cancer Res, 11 (2013) 294-302. [PubMed: 23345604]
Huang C, Li Y, Guo Y, Zhang Z, Lian G, Chen Y, Li J, Su Y, Li J, Yang K, Chen S, Su H, Huang K, Zeng L, MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells, Theranostics, 8 (2018) 3074-3086. [PubMed: 29896303]
Fujisawa T, Shimamura T, Goto K, Nakagawa R, Muroyama R, Ino Y, Horiuchi H, Endo I, Maeda S, Harihara Y, Nakajima A, Matsuhashi N, Kato N, Isayama H, Puri A, Suzuki A, Bellayr I, Leland P, Joshi BH, Puri RK, A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma, Cancers (Basel), 12 (2020).
Furuhashi S, Sakaguchi T, Murakami T, Fukushima M, Morita Y, Ikegami K, Kikuchi H, Setou M, Takeuchi H, Tenascin C in the Tumor-Nerve Microenvironment Enhances Perineural Invasion and Correlates With Locoregional Recurrence in Pancreatic Ductal Adenocarcinoma, Pancreas, 49 (2020) 442-454. [PubMed: 32132519]
Zhang JF, Tao LY, Yang MW, Xu DP, Jiang SH, Fu XL, Liu DJ, Huo YM, Liu W, Yang JY, Hua R, Lu P, Sun YW, CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma, Cancer Lett, 508 (2021) 47-58. [PubMed: 33766751]
Eibl G, Reber HA, A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer, Pancreas, 31 (2005) 258-262. [PubMed: 16163058]
Koide N, Yamada T, Shibata R, Mori T, Fukuma M, Yamazaki K, Aiura K, Shimazu M, Hirohashi S, Nimura Y, Sakamoto M, Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, 12 (2006) 2419-2426. [PubMed: 16638847]
Saloman JL, Albers KM, Li D, Hartman DJ, Crawford HC, Muha EA, Rhim AD, Davis BM, Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer, Proceedings of the National Academy of Sciences of the United States of America, 113 (2016) 3078-3083. [PubMed: 26929329]
Jurcak NR, Rucki AA, Muth S, Thompson E, Sharma R, Ding D, Zhu Q, Eshleman JR, Anders RA, Jaffee EM, Fujiwara K, Zheng L, Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice, Gastroenterology, 157 (2019) 838-850.e836. [PubMed: 31163177]
Yang MW, Tao LY, Jiang YS, Yang JY, Huo YM, Liu DJ, Li J, Fu XL, He R, Lin C, Liu W, Zhang JF, Hua R, Li Q, Jiang SH, Hu LP, Tian GA, Zhang XX, Niu N, Lu P, Shi J, Xiao GG, Wang LW, Xue J, Zhang ZG, Sun YW, Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma, Cancer research, 80 (2020) 1991-2003. [PubMed: 32098780]
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer, Science, 324 (2009) 1457-1461. [PubMed: 19460966]
Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA, CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer, Proceedings of the National Academy of Sciences of the United States of America, 110 (2013) 12325-12330. [PubMed: 23836645]
Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, Popović Z, Huang P, Bawendi MG, Boucher Y, Jain RK, Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels, Nat Commun, 4 (2013) 2516. [PubMed: 24084631]
Hwang HJ, Oh MS, Lee DW, Kuh HJ, Multiplex quantitative analysis of stroma-mediated cancer cell invasion, matrix remodeling, and drug response in a 3D co-culture model of pancreatic tumor spheroids and stellate cells, J Exp Clin Cancer Res, 38 (2019) 258. [PubMed: 31200779]
Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T, Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring, Nature, 569 (2019) 131-135. [PubMed: 30996350]
Suklabaidya S, Dash P, Das B, Suresh V, Sasmal PK, Senapati S, Experimental models of pancreatic cancer desmoplasia, Lab Invest, 98 (2018) 27-40. [PubMed: 29155423]
Helms E, Onate MK, Sherman MH, Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment, Cancer discovery, (2020).
Suklabaidya S, Dash P, Das B, Suresh V, Sasmal PK, Senapati S, Experimental models of pancreatic cancer desmoplasia, Laboratory Investigation, 98 (2018) 27-40. [PubMed: 29155423]
Steer A, Cordes N, Jendrossek V, Klein D, Impact of Cancer-Associated Fibroblast on the Radiation-Response of Solid Xenograft Tumors, Front Mol Biosci, 6 (2019) 70-70. [PubMed: 31475157]
Nguyen AH, Li L, Toste PA, Wu N, Donahue TR, MicroRNAs in Pancreatic Fibroblast Induced by Tumor Cells, Journal of the American College of Surgeons, 219 (2014) S130.
Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y, Ando K, Weng L, Ishihara S, Ponik SM, Conklin MW, Haga H, Nagasaka A, Miyata T, Matsuyama M, Kobayashi T, Fujii T, Yamada S, Yamaguchi J, Wang T, Woods SL, Worthley D, Shimamura T, Fujishiro M, Hirooka Y, Enomoto A, Takahashi M, Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis, Cancer research, 79 (2019) 5367-5381. [PubMed: 31439548]
Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, Giri B, Ferrantella A, Dudeja V, Saluja A, Banerjee S, Targeting tumor-intrinsic metabolic node sensitizes pancreatic cancer to anti-PD1 therapy, bioRxiv, (2019) 519462.
Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, Giri B, Ferrantella A, Dudeja V, Saluja A, Banerjee S, Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy, The Journal of clinical investigation, 130 (2020) 451-465. [PubMed: 31613799]
Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, Honselmann KC, Rosenbaum MW, Nahar S, Kem M, Ferrone CR, Lillemoe KD, Bardeesy N, Ryan DP, Thayer SP, Warshaw AL, Fernandez-Del Castillo C, Liss AS, Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival, PLoS One, 12 (2017) e0182855. [PubMed: 28854237]
Strobel O, Dor Y, Alsina J, Stirman A, Lauwers G, Trainor A, Castillo CF, Warshaw AL, Thayer SP, In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia, Gastroenterology, 133 (2007) 1999-2009. [PubMed: 18054571]
Kopinke D, Brailsford M, Shea JE, Leavitt R, Scaife CL, Murtaugh LC, Lineage tracing reveals the dynamic contribution of cells to the developing and adult pancreas, Development, 138 (2011) 431. [PubMed: 21205788]
Gu G, Brown JR, Melton DA, Direct lineage tracing reveals the ontogeny of pancreatic cell fates during mouse embryogenesis, Mechanisms of Development, 120 (2003) 35-43. [PubMed: 12490294]
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ, EMT and dissemination precede pancreatic tumor formation, Cell, 148 (2012) 349-361. [PubMed: 22265420]
Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, Maitra A, Leach SD, DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer, Gastroenterology, 146 (2014) 245-256. [PubMed: 24096005]
Westphalen CB, Takemoto Y, Tanaka T, Macchini M, Jiang Z, Renz BW, Chen X, Ormanns S, Nagar K, Tailor Y, May R, Cho Y, Asfaha S, Worthley DL, Hayakawa Y, Urbanska AM, Quante M, Reichert M, Broyde J, Subramaniam PS, Remotti H, Su GH, Rustgi AK, Friedman RA, Honig B, Califano A, Houchen CW, Olive KP, Wang TC, Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis, Cell Stem Cell, 18 (2016) 441-455. [PubMed: 27058937]
Qiu W, Remotti HE, Tang SM, Wang E, Dobberteen L, Lee Youssof A, Lee JH, Cheung EC, Su GH, Pancreatic DCLK1(+) cells originate distinctly from PDX1(+) progenitors and contribute to the initiation of intraductal papillary mucinous neoplasm in mice, Cancer Lett, 423 (2018) 71-79. [PubMed: 29526803]
Glenn ST, Jones CA, Sexton S, LeVea CM, Caraker SM, Hajduczok G, Gross KW, Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma, Oncogene, 33 (2014) 5706-5715. [PubMed: 24292676]
Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, Link J, Pelz C, Heiser LM, Morton JP, Muthalagu N, Hoffman MT, Manning SL, Pratt ED, Kendsersky ND, Egbukichi N, Amery TS, Thoma MC, Jenny ZP, Rhim AD, Murphy DJ, Sansom OJ, Crawford HC, Sheppard BC, Sears RC, MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance, Nat Commun, 8 (2017) 1728. [PubMed: 29170413]
Kopp JL, Dubois CL, Schaeffer DF, Samani A, Taghizadeh F, Cowan RW, Rhim AD, Stiles BL, Valasek M, Sander M, Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice, Gastroenterology, 154 (2018) 1509-1523.e1505. [PubMed: 29273451]
Mameishvili E, Serafimidis I, Iwaszkiewicz S, Lesche M, Reinhardt S, Bölicke N, Buttner M, Stellas D, Papadimitropoulou A, Szabolcs M, Anastassiadis K, Dahl A, Theis F, Efstratiadis A, Gavalas A, Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer, Proceedings of the National Academy of Sciences of the United States of America, 116 (2019) 20679-20688. [PubMed: 31548432]
Tisdale MJ, Biology of cachexia, J Natl Cancer Inst, 89 (1997) 1763-1773. [PubMed: 9392617]
Henderson SE, Makhijani N, Mace TA, Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models, Pancreas, 47 (2018) 937-945. [PubMed: 30113428]
Wigmore SJ, Plester CE, Richardson RA, Fearon KC, Changes in nutritional status associated with unresectable pancreatic cancer, Br J Cancer, 75 (1997) 106-109. [PubMed: 9000606]
Ronga I, Gallucci F, Riccardi F, Uomo G, Anorexia-cachexia syndrome in pancreatic cancer: recent advances and new pharmacological approach, Adv Med Sci, 59 (2014) 1-6. [PubMed: 24797965]
Fearon KC, Glass DJ, Guttridge DC, Cancer cachexia: mediators, signaling, and metabolic pathways, Cell Metab, 16 (2012) 153-166. [PubMed: 22795476]
Zhou W, Jiang ZW, Tian J, Jiang J, Li N, Li JS, Role of NF-kappaB and cytokine in experimental cancer cachexia, World J Gastroenterol, 9 (2003) 1567-1570. [PubMed: 12854165]
Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG, Zimmers TA, JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia, Am J Physiol Endocrinol Metab, 303 (2012) E410-421. [PubMed: 22669242]
Greco SH, Tomkotter L, Vahle AK, Rokosh R, Avanzi A, Mahmood SK, Deutsch M, Alothman S, Alqunaibit D, Ochi A, Zambirinis C, Mohaimin T, Rendon M, Levie E, Pansari M, Torres Hernandez A, Daley D, Barilla R, Pachter HL, Tippens D, Malik H, Boutajangout A, Wisniewski T, Miller G, TGF-beta Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia, PLoS One, 10 (2015) e0132786. [PubMed: 26172047]
Yakovenko A, Cameron M, Trevino JG, Molecular therapeutic strategies targeting pancreatic cancer induced cachexia, World J Gastrointest Surg, 10 (2018) 95-106. [PubMed: 30622678]
Pu N, Zhao G, Yin H, Li JA, Nuerxiati A, Wang D, Xu X, Kuang T, Jin D, Lou W, Wu W, CD25 and TGF-beta blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer, J Transl Med, 16 (2018) 294. [PubMed: 30359281]
Zhu X, Burfeind KG, Michaelis KA, Braun TP, Olson B, Pelz KR, Morgan TK, Marks DL, MyD88 signalling is critical in the development of pancreatic cancer cachexia, J Cachexia Sarcopenia Muscle, 10 (2019) 378-390. [PubMed: 30666818]
Michaelis KA, Zhu X, Burfeind KG, Krasnow SM, Levasseur PR, Morgan TK, Marks DL, Establishment and characterization of a novel murine model of pancreatic cancer cachexia, J Cachexia Sarcopenia Muscle, 8 (2017) 824-838. [PubMed: 28730707]
Markov SD, Gonzalez D, Mehla K, Preclinical Models for Studying the Impact of Macrophages on Cancer Cachexia, Current Protocols in Pharmacology, 91 (2020) e80. [PubMed: 33264501]
Shukla SK, Markov SD, Attri KS, Vernucci E, King RJ, Dasgupta A, Grandgenett PM, Hollingsworth MA, Singh PK, Yu F, Mehla K, Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia, Cancer Lett, 484 (2020) 29-39. [PubMed: 32344015]
Leach SD, Mouse models of pancreatic cancer: the fur is finally flying!, Cancer cell, 5 (2004) 7-11. [PubMed: 14749121]
Shen R, Wang Q, Cheng S, Liu T, Jiang H, Zhu J, Wu Y, Wang L, The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models, Cancer Letters, 339 (2013) 135-143. [PubMed: 23887057]
Westphalen CB, Olive KP, Genetically engineered mouse models of pancreatic cancer, Cancer J, 18 (2012) 502-510. [PubMed: 23187836]
Guerra C, Barbacid M, Genetically engineered mouse models of pancreatic adenocarcinoma, Molecular Oncology, 7 (2013) 232-247. [PubMed: 23506980]
Krah NM, De La O J-P, Swift GH, Hoang CQ, Willet SG, Chen Pan F, Cash GM, Bronner MP, Wright CV, MacDonald RJ, Murtaugh LC, The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma, eLife, 4 (2015) e07125.
Ma L, Saiyin H, LSL-KrasG12D; LSL-Trp53R172H/+; Ink4flox/+; Ptf1/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer, PLOS ONE, 12 (2017) e0176844. [PubMed: 28475592]
Veite-Schmahl MJ, Joesten WC, Kennedy MA, HMGA1 expression levels are elevated in pancreatic intraepithelial neoplasia cells in the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer, British Journal of Cancer, 117 (2017) 639-647. [PubMed: 28697176]
Feng J, Lin A, Chen X, Wang D, Wong M, Zhang G, Na J, Zhang T, Chen Z, Chen Y-T, Nancy Du Y-C, High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer, bioRxiv, (2021) 2021.2002.2019.432042.
Saborowski M, Saborowski A, Morris J.P.t., Bosbach B, Dow LE, Pelletier J, Klimstra DS, Lowe SW, A modular and flexible ESC-based mouse model of pancreatic cancer, Genes & development, 28 (2014) 85-97. [PubMed: 24395249]
Xie Y, Zhu S, Zhong M, Yang M, Sun X, Liu J, Kroemer G, Lotze M, Zeh HJ 3rd, Kang R, Tang D, Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma, Gastroenterology, 153 (2017) 1429-1443.e1425. [PubMed: 28764929]
Humpton TJ, Alagesan B, DeNicola GM, Lu D, Yordanov GN, Leonhardt CS, Yao MA, Alagesan P, Zaatari MN, Park Y, Skepper JN, Macleod KF, Perez-Mancera PA, Murphy MP, Evan GI, Vousden KH, Tuveson DA, Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer, Cancer discovery, 9 (2019) 1268-1287. [PubMed: 31263025]
Hamada S, Taguchi K, Masamune A, Yamamoto M, Shimosegawa T, Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis, Carcinogenesis, 38 (2017) 661-670. [PubMed: 29240881]
Das M, Shen L, Liu Q, Goodwin TJ, Huang L, Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer, Molecular therapy : the journal of the American Society of Gene Therapy, 27 (2019) 507-517. [PubMed: 30545600]
Na'ara S, Amit M, Gil Z, L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression, Oncogene, 38 (2019) 596-608. [PubMed: 30171263]
Chugh S, Barkeer S, Rachagani S, Nimmakayala RK, Perumal N, Pothuraju R, Atri P, Mahapatra S, Thapa I, Talmon GA, Smith LM, Yu X, Neelamegham S, Fu J, Xia L, Ponnusamy MP, Batra SK, Disruption of C1galt1 Gene Promotes Development and Metastasis of Pancreatic Adenocarcinomas in Mice, Gastroenterology, 155 (2018) 1608-1624. [PubMed: 30086262]
Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T, The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer, Nature cell biology, 19 (2017) 518-529. [PubMed: 28414315]
Zhou C, Qian W, Ma J, Cheng L, Jiang Z, Yan B, Li J, Duan W, Sun L, Cao J, Wang F, Wu E, Wu Z, Ma Q, Li X, Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1, Cell proliferation, 52 (2019) e12514. [PubMed: 30341797]
Nimmakayala RK, Seshacharyulu P, Lakshmanan I, Rachagani S, Chugh S, Karmakar S, Rauth S, Vengoji R, Atri P, Talmon GA, Lele SM, Smith LM, Thapa I, Bastola D, Ouellette MM, Batra SK, Ponnusamy MP, Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1, Gastroenterology, 155 (2018) 892-908.e896. [PubMed: 29864419]
Gupta S, Prajapati A, Gulati M, Gautam SK, Kumar S, Dalal V, Talmon GA, Rachagani S, Jain M, Irreversible and sustained upregulation of endothelin axis during oncogene-associated pancreatic inflammation and cancer, Neoplasia, 22 (2020) 98-110. [PubMed: 31923844]
Nimmakayala RK, Leon F, Rachagani S, Rauth S, Nallasamy P, Marimuthu S, Shailendra GK, Chhonker YS, Chugh S, Chirravuri R, Gupta R, Mallya K, Prajapati DR, Lele SM, T CC, J LG, Grandgenett PM, Hollingsworth MA, Murry DJ, Batra SK, Ponnusamy MP, Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma, Oncogene, 40 (2021) 215-231. [PubMed: 33110235]
Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, Hingorani SR, Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas, Cancer cell, 11 (2007) 229-243. [PubMed: 17349581]
Yin X, Su J, Zhou X, Guo J, Wei W, Wang Z, K-ras-driven engineered mouse models for pancreatic cancer, Discov Med, 19 (2015) 15-21. [PubMed: 25636957]
Rossi Sebastiano M, Pozzato C, Saliakoura M, Yang Z, Peng R-W, Galiè M, Oberson K, Simon H-U, Karamitopoulou E, Konstantinidou G, ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression, Science Advances, 6 (2020) eabb9200. [PubMed: 33127675]
Mucciolo G, Curcio C, Roux C, Li WY, Capello M, Curto R, Chiarle R, Giordano D, Satolli MA, Lawlor R, Scarpa A, Lukac P, Stakheev D, Provero P, Vannucci L, Mak TW, Novelli F, Cappello P, IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions, Proceedings of the National Academy of Sciences, 118 (2021) e2020395118.
Vohra R, Park J, Wang YN, Gravelle K, Whang S, Hwang JH, Lee D, Evaluation of pancreatic tumor development in KPC mice using multi-parametric MRI, Cancer Imaging, 18 (2018) 41. [PubMed: 30409175]
Kawano T, Murata M, Kang JH, Piao JS, Narahara S, Hyodo F, Hamano N, Guo J, Oguri S, Ohuchida K, Hashizume M, Ultrasensitive MRI detection of spontaneous pancreatic tumors with nanocage-based targeted contrast agent, Biomaterials, 152 (2018) 37-46. [PubMed: 29107217]
Goetze RG, Buchholz SM, Patil S, Petzold G, Ellenrieder V, Hessmann E, Neesse A, Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models, J Vis Exp, (2018).
Gürlevik E, Fleischmann-Mundt B, Brooks J, Demir IE, Steiger K, Ribback S, Yevsa T, Woller N, Kloos A, Ostroumov D, Armbrecht N, Manns MP, Dombrowski F, Saborowski M, Kleine M, Wirth TC, Oettle H, Ceyhan GO, Esposito I, Calvisi DF, Kubicka S, Kuhnel F, Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells, Gastroenterology, 151 (2016) 338-350.e337. [PubMed: 27210037]
Li J, Betzler C, Lohneis P, Popp MC, Qin J, Kalinski T, Wartmann T, Bruns CJ, Zhao Y, Popp FC, The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer, Int J Mol Sci, 21 (2020).
Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I, From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer, Nat Rev Clin Oncol, 17 (2020) 108-123. [PubMed: 31705130]
Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH, Therapeutic developments in pancreatic cancer: current and future perspectives, Nat Rev Gastroenterol Hepatol, 15 (2018) 333-348. [PubMed: 29717230]
Fanchon LM, Russell J, Pillarsetty N, O'Donoghue I, Gangangari K, Yu KH, Humm JL, Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma, PLoS One, 15 (2020) e0231745. [PubMed: 32298392]
Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA, nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer, Cancer discovery, 2 (2012) 260-269. [PubMed: 22585996]
Bhutiani N, Li Y, Zheng Q, Pandit H, Shi X, Chen Y, Yu Y, Pulliam ZR, Tan M, Martin RCG 2nd, Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma, Annals of surgical oncology, 27 (2020) 4348-4359. [PubMed: 32681477]
Russell J, Pillarsetty N, Kramer RM, Romesser PB, Desai P, Haimovitz-Friedman A, Lowery MA, Humm JL, In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models, Mol Imaging Biol, 19 (2017) 885-892. [PubMed: 28349292]
Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA, SPARC independent drug delivery and antitumour effects of nab</ em>-paclitaxel in genetically engineered mice, Gut, 63 (2014) 974. [PubMed: 24067278]
Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR, Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects, Clinical cancer research : an official journal of the American Association for Cancer Research, 11 (2005) 8773-8781. [PubMed: 16361565]
Gold DV, Modrak DE, Schutsky K, Cardillo TM, Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft, Int J Cancer, 109 (2004) 618-626. [PubMed: 14991585]
Ng SS, Tsao MS, Nicklee T, Hedley DW, Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice, Clinical cancer research : an official journal of the American Association for Cancer Research, 7 (2001) 3269-3275. [PubMed: 11595724]
Zhang X, Galardi E, Duquette M, Lawler J, Parangi S, Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model, Clinical cancer research : an official journal of the American Association for Cancer Research, 11 (2005) 5622-5630. [PubMed: 16061881]
Modi S, Kir D, Giri B, Majumder K, Arora N, Dudeja V, Banerjee S, Saluja AK, Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 20 (2016) 13-23; discussion 23-14. [PubMed: 26503259]
Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH, Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer, Cancer research, 65 (2005) 9064-9072. [PubMed: 16204081]
Alisauskus R, Wong GY, Gold DV, Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer, Cancer research, 55 (1995) 5743s-5748s. [PubMed: 7493339]
Gold DV, Cardillo T, Vardi Y, Blumenthal R, Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4, Int J Cancer, 71 (1997) 660-667. [PubMed: 9178823]
Yamamoto A, Sawada T, Yamashita Y, Nishihara T, Ho JJ, Kim Y, Chung KH, Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 131I-labeled chimeric monoclonal antibody Nd2, Oncol Rep, 6 (1999) 179-184. [PubMed: 9864424]
Song CW, Griffin RJ, Lee Y-J, Cho H, Seo J, Park I, Kim HK, Kim DH, Kim M-S, Dusenbery KE, Cho LC, Reoxygenation and Repopulation of Tumor Cells after Ablative Hypofractionated Radiotherapy (SBRT and SRS) in Murine Tumors, Radiation Research, 192 (2019) 159-168. [PubMed: 31188068]
Taniguchi CM, Molkentine J, Fujimoto TN, Colbert LE, Deorukhkar A, Herman JM, Effect of stereotactic radiation (SBRT) on survival in a preclinical model of spontaneous pancreatic cancer with induction gemcitabine/nab-paclitaxel, Journal of Clinical Oncology, 36 (2018) 273-273.
Dobiasch S, Kampfer S, Habermehl D, Duma MN, Felix K, Strauss A, Schilling D, Wilkens JJ, Combs SE, MRI-based high-precision irradiation in an orthotopic pancreatic tumor mouse model, Strahlentherapie und Onkologie, 194 (2018) 944-952. [PubMed: 29947818]
Taylor E, Zhou J, Lindsay P, Foltz W, Cheung M, Siddiqui I, Hosni A, Amir AE, Kim J, Hill RP, Jaffray DA, Hedley DW, Quantifying Reoxygenation in Pancreatic Cancer During Stereotactic Body Radiotherapy, Scientific Reports, 10 (2020) 1638. [PubMed: 32005829]
Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S, Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle, J Gastrointest Oncol, 9 (2018) 1014-1026. [PubMed: 30603120]
Mills BN, Connolly KA, Ye J, Murphy JD, Uccello TP, Han BJ, Zhao T, Drage MG, Murthy A, Qiu H, Patel A, Figueroa NM, Johnston CJ, Prieto PA, Egilmez NK, Belt BA, Lord EM, Linehan DC, Gerber SA, Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment, Cell Rep, 29 (2019) 406-421.e405. [PubMed: 31597100]
Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, Twyman-Saint Victor C, Vonderheide RH, Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer, Cancer research, 78 (2018) 4282-4291. [PubMed: 29844122]
Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P, Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial, JAMA Oncol, 5 (2019) 1276-1282. [PubMed: 31294749]
Yasmin-Karim S, Bruck PT, Moreau M, Kunjachan S, Chen GZ, Kumar R, Grabow S, Dougan SK, Ngwa W, Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer, Front Immunol, 9 (2018) 2030. [PubMed: 30245691]
Yasmin-Karim S, Bruck PT, Moreau M, Kunjachan S, Chen GZ, Kumar R, Grabow S, Dougan SK, Ngwa W, Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer, Frontiers in Immunology, 9 (2018).
Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, Demir IE, Armbrecht N, Ceyhan GO, Manns MP, Wirth TC, Kubicka S, Bernhardt G, Smyth MJ, Calvisi DF, Gürlevik E, Kühnel F, Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer, Cancer research, 78 (2018) 475-488. [PubMed: 29180478]
Yoshii Y, Matsumoto H, Yoshimoto M, Oe Y, Zhang MR, Nagatsu K, Sugyo A, Tsuji AB, Higashi T, (64)Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer, J Nucl Med, 60 (2019) 1437-1443. [PubMed: 30850497]
Pfitzinger PL, Fangmann L, Wang K, Demir E, Gürlevik E, Fleischmann-Mundt B, Brooks J, D'Haese JG, Teller S, Hecker A, Jesinghaus M, Jäger C, Ren L, Istvanffy R, Kuhnel F, Friess H, Ceyhan GO, Demir IE, Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation, J Exp Clin Cancer Res, 39 (2020) 289. [PubMed: 33357230]
Balachandran VP, Beatty GL, Dougan SK, Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities, Gastroenterology, 156 (2019) 2056-2072. [PubMed: 30660727]
Wang W, Marinis JM, Beal AM, Savadkar S, Wu Y, Khan M, Taunk PS, Wu N, Su W, Wu J, Ahsan A, Kurz E, Chen T, Yaboh I, Li F, Gutierrez J, Diskin B, Hundeyin M, Reilly M, Lich JD, Harris PA, Mahajan MK, Thorpe JH, Nassau P, Mosley JE, Leinwand J, Kochen Rossi JA, Mishra A, Aykut B, Glacken M, Ochi A, Verma N, Kim JI, Vasudevaraja V, Adeegbe D, Almonte C, Bagdatlioglu E, Cohen DJ, Wong KK, Bertin J, Miller G, RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer, Cancer cell, 34 (2018) 757-774.e757. [PubMed: 30423296]
Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen H, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD, Hingorani SR, T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma, Cancer cell, 28 (2015) 638-652. [PubMed: 26525103]
Raj D, Yang MH, Rodgers D, Hampton EN, Begum J, Mustafa A, Lorizio D, Garces I, Propper D, Kench JG, Kocher HM, Young TS, Aicher A, Heeschen C, Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma, Gut, 68 (2019) 1052-1064. [PubMed: 30121627]
Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, Woolman S, Vithayathil T, Glickman LH, Ndubaku CO, McWhirter SM, Dubensky TW Jr., Armstrong TD, Jaffee EM, Zaidi N, Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer, JCI Insight, 3 (2018).
Gopinathan A, Morton JP, Jodrell DI, Sansom OJ, GEMMs as preclinical models for testing pancreatic cancer therapies, Disease models & mechanisms, 8 (2015) 1185-1200. [PubMed: 26438692]
Lee JW, Komar CA, Bengsch F, Graham K, Beatty GL, Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;
LSL-Trp53(R172H/+) ;
Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery, Curr Protoc Pharmacol, 73 (2016) 14.39.11-14.39.20. [PubMed: 27248578]
Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T, Yamashita Y, Yamada N, Ohira M, Hirakawa K, Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine, Clinical cancer research : an official journal of the American Association for Cancer Research, 12 (2006) 4925-4932. [PubMed: 16914581]
Larbouret C, Gaborit N, Chardes T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pelegrin A, In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption, Neoplasia, 14 (2012) 121-130. [PubMed: 22431920]
DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM, Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 10 (2006) 1291-1300; discussion 1300. [PubMed: 17114015]
Derosier LC, Vickers SM, Zinn KR, Huang Z, Wang W, Grizzle WE, Sellers J, Stockard CR Jr., Zhou T, Oliver PG, Arnoletti P, Lobuglio AF, Buchsbaum DJ, TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth, Molecular cancer therapeutics, 6 (2007) 3198-3207. [PubMed: 18089714]
Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A, Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5, Cell death and differentiation, 15 (2008) 751-761. [PubMed: 18219321]
Danielczyk A, Stahn R, Faulstich D, Loffler A, Marten A, Karsten U, Goletz S, PankoMab: a potent new generation anti-tumour MUC1 antibody, Cancer immunology, immunotherapy : CII, 55 (2006) 1337-1347.
Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L, Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin, Cancer immunity, 7 (2007) 20. [PubMed: 18088084]
Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL, IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor, Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (2007) 5549s- 5555s. [PubMed: 17875788]
Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, Tsang KY, Surawski RJ, Scott T, Camphausen K, Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts, Clinical cancer research : an official journal of the American Association for Cancer Research, 12 (2006) 4983-4988. [PubMed: 16914588]
Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, Science, 331 (2011) 1612-1616. [PubMed: 21436454]
Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT, Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti PD-L1 immunotherapy in pancreatic cancer, Proceedings of the National Academy of Sciences of the United States of America, 110 (2013) 20212-20217. [PubMed: 24277834]
Dreau D, Moore LJ, Wu M, Roy LD, Dillion L, Porter T, Puri R, Momin N, Wittrup KD, Mukherjee P, Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma, Frontiers in oncology, 9 (2019) 330. [PubMed: 31114758]
Song HK, Hwang DY, Use of C57BL/6N mice on the variety of immunological researches, Lab Anim Res, 33 (2017) 119-123. [PubMed: 28747977]
Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A, Innate immune response in Th1-and Th2-dominant mouse strains, Shock (Augusta, Ga.), 22 (2004) 460-466.
Banerjee K, Kumar S, Ross KA, Gautam S, Poelaert B, Nasser MW, Aithal A, Bhatia R, Wannemuehler MJ, Narasimhan B, Solheim JC, Batra SK, Jain M, Emerging trends in the immunotherapy of pancreatic cancer, Cancer Letters, 417 (2018) 35-46. [PubMed: 29242097]
Shangguan A, Shang N, Figini M, Pan L, Yang J, Ma Q, Hu S, Eresen A, Sun C, Wang B, Velichko Y, Yaghmai V, Zhang Z, Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model, Cytotherapy, 22 (2020) 6-15. [PubMed: 32005355]
Schizas D, Charalampakis N, Kole C, Economopoulou P, Koustas E, Gkotsis E, Ziogas D, Psyrri A, Karamouzis MV, Immunotherapy for pancreatic cancer: A 2020 update, Cancer treatment reviews, 86 (2020) 102016. [PubMed: 32247999]
Gautam SK, Kumar S, Dam V, Ghersi D, Jain M, Batra SK, MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy, Seminars in Immunology, 47 (2020) 101391. [PubMed: 31952903]
Banerjee K, Gautam SK, Kshirsagar P, Ross KA, Spagnol G, Sorgen P, Wannemuehler MJ, Narasimhan B, Solheim JC, Kumar S, Batra SK, Jain M, Amphiphilic polyanhydride-based recombinant MUC4β-nanovaccine activates dendritic cells, Genes & cancer, 10 (2019) 52-62. [PubMed: 31258832]
Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O, Johns AL, Mead RS, Gill AJ, Chang DK, McKay SH, Chantrill LA, Chin VT, Chou A, Humphris JL, Pajic M, Steinmann A, Arshi M, Drury A, Froio D, Morgan A, Timpson P, Hermann D, Vennin C, Warren S, Pinese M, Wu J, Pinho AV, Mead RS, Tucker K, Andrews L, Gill AJ, Samra JS, Arena J, Pavlakis N, High HA, Mittal A, Chang DK, Biankin AV, Bailey P, Martin S, Musgrove EA, Jones MD, Nourse C, Jamieson NB, Chou A, Chantrill LA, Stoita A, Williams D, Spigelman A, Waddell N, Pearson JV, Patch A-M, Nones K, Newell F, Mukhopadhyay P, Addala V, Kazakoff S, Holmes O, Leonard C, Wood S, Xu C, Grimmond SM, Hofmann O, Wilson PJ, Christ A, Bruxner T, Asghari R, Merrett ND, Pavey D, Das A, Goodwin A, Cosman PH, Ismail K, O'Connor C, Cooper CL, Goodwin A, Grimison P, Kench JG, Sandroussi C, Lam VW, McLeod D, Nagrial AM, Kirk J, James V, Texler M, Forest C, Epari KP, Ballal M, Fletcher DR, Mukhedkar S, Zeps N, Beilin M, Feeney K, Nguyen NQ, Ruszkiewicz AR, Worthley C, Chen J, Brooke-Smith ME, Papangelis V, Clouston AD, Martin P, Barbour AP, O'Rourke TJ, Fawcett JW, Slater K, Hatzifotis M, Hodgkinson P, Nikfarjam M, Eshleman JR, Hruban RH, Wolfgang CL, Hodgin M, Scarpa A, Lawlor RT, Beghelli S, Corbo V, Scardoni M, Bassi C, Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, lacobuzio Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD, I. Australian Pancreatic Cancer Genome, R. Garvan Institute of Medical, H. Prince of Wales, H. Royal North Shore, G. University of, H. St Vincent's, Q.B.M.R. Institute, C.f.C.R. University of Melbourne, I.f.M.B. University of Queensland, H. Bankstown, H. Liverpool, C.O.B.L. Royal Prince Alfred Hospital, H. Westmead, Fremantle H, H. St John of God, H. Royal Adelaide, C. Flinders Medical, P. Envoi, H. Princess Alexandria, H. Austin, I. Johns Hopkins Medical, A.R.-N.C.f.A.R.o. Cancer, Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, 551 (2017) 512-516. [PubMed: 29132146]
Spear S, McNeish IA, Capasso M, Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity, J Vis Exp, (2019).
Morikane K, Tempero R, Sivinski CL, Kitajima S, Gendler SJ, Hollingsworth MA, Influence of organ site and tumor cell type on MUC1-specific tumor immunity, International immunology, 13 (2001) 233-240. [PubMed: 11157856]
Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ, Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model, Cancer research, 58 (1998) 315-321. [PubMed: 9443411]
Huang M, Zhang W, Guo J, Wei X, Phiwpan K, Zhang J, Zhou X, Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation, Scientific Reports, 6 (2016) 33612. [PubMed: 27634283]
Zeng Y, Gao T, Zhao G, Jiang Y, Yang Y, Yu H, Kou Z, Lone Y, Sun S, Zhou Y, Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation, Hum Vaccin Immunother, 12 (2016) 829-836. [PubMed: 26479036]
Eggel A, Wyss-Coray T, A revival of parabiosis in biomedical research, Swiss Med Wkly, 144 (2014) w13914. [PubMed: 24496774]
Conboy MJ, Conboy IM, Rando TA, Heterochronic parabiosis: historical perspective and methodological considerations for studies of aging and longevity, Aging Cell, 12 (2013) 525- 530. [PubMed: 23489470]
Kross I, Parabiosis and Tumor Growth, Cancer research, 10 (1921) 121-126.
Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK, Hematogenous metastasis of ovarian cancer: rethinking mode of spread, Cancer cell, 26 (2014) 77-91. [PubMed: 25026212]
Feng N, Luo JM, Guo X, The immune influence of a parabiosis model on tumour-bearing mice, Swiss Med Wkly, 148 (2018) w14678. [PubMed: 30294773]
Arina A, Idel C, Hyjek EM, Alegre ML, Wang Y, Bindokas VP, Weichselbaum RR, Schreiber H, Tumor-associated fibroblasts predominantly come from local and not circulating precursors, Proceedings of the National Academy of Sciences of the United States of America, 113 (2016) 7551-7556. [PubMed: 27317748]
Franklin RA, Li MO, Determining Leukocyte Origins Using Parabiosis in the PyMT Breast Tumor Model, Bio Protoc, 5 (2015).
Warren S, Carlstein RG, Steinke J, Chute RN, Island-Cell Tumors in Irradiated Rats in Parabiosis, Proc Soc Exp Biol Med, 115 (1964) 910-912. [PubMed: 14166605]
Nakamura T, Kuwai T, Kim JS, Fan D, Kim SJ, Fidler IJ, Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice, Neoplasia, 9 (2007) 979-986. [PubMed: 18030366]
Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ, DeNardo DG, Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression, Immunity, 47 (2017) 597. [PubMed: 28930665]
Lee AYL, Dubois CL, Sarai K, Zarei S, Schaeffer DF, Sander M, Kopp JL, Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma, Gut, 68 (2019) 487-498. [PubMed: 29363536]
Maddipati R, Stanger BZ, Pancreatic Cancer Metastases Harbor Evidence of Polyclonality, Cancer discovery, 5 (2015) 1086-1097. [PubMed: 26209539]
Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, Miller DK, Christ AN, Bruxner TJC, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, lacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey U-MH, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM, I. Australian Pancreatic Cancer Genome, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531 (2016) 47-52. [PubMed: 26909576]
Collisson EA, Bailey P, Chang DK, Biankin AV, Molecular subtypes of pancreatic cancer, Nat Rev Gastroenterol Hepatol, 16 (2019) 207-220. [PubMed: 30718832]